Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis

Yonsei Medical Journal

Volumn 53, Issue 5, 2012, Pages 1045-1048

  Cantarini, Luca ^a   Giani, Teresa ^b   Fioravanti, Antonella ^a   Iacoponi, Francesca ^a   Simonini, Gabriele ^b   Pagnini, Ilaria ^b   Spreafico, Adriano ^a   Chellini, Federico ^a   Galeazzi, Mauro ^a   Cimaz, Rolando ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Disease activity; Inflammatory markers; Juvenile idiopathic arthritis; Serum amyloid A

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; SERUM AMYLOID A;

ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; POLYARTHRITIS;

ARTHRITIS, JUVENILE RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; SERUM AMYLOID A PROTEIN;

EID: 84864614091     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2012.53.5.1045     Document Type: Article

References (12)

1. Husby G, Marhaug G, Dowtor B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid 1994;1:119-37.
2. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265:501-23.
3. Jung SY, Park MC, Park YB, Lee SK. Serum amyloid A as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J 2007;48:218-24.
4. Lange U, Boss B, Teichmann J, Klör HU, Neeck G. Serum amyloid A--an indicator of inflammation in ankylosing spondylitis. Rheumatol Int 2000;19:119-22.
5. Cleary AG, Sills JA, Davidson JE. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 2000;27:1568.
6. O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2000;2:142-4.
7. Shimojima Y, Matsuda M, Gono T, Ishii W, Ikeda S. Serum amyloid A as a potent therapeutic marker in a refractory patient with polymyalgia rheumatica. Intern Med 2005;44:1009-12.
8. de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009;61:1484-90.
9. Scheinberg MA, Hubscher O, Morteo OG, Benson MD. Serum amyloid protein levels in south american children with rheumatoid arthritis: a co-operative study. Ann Rheum Dis 1980;39:228-30.
10. Hachulla E, Saile R, Parra HJ, Hatron PY, Gosset D, Fruchart JC, et al. Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease. Clin Exp Rheumatol 1991;9:157-63.
11. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004;314:363-9.
12. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999;37:381-8.